The University of Massachusetts Board of Directors has selected Dr. David D. McManus to serve as the next chancellor of the UMass Chan Medical School. The decision, reached during a virtual meeting on Tuesday, April 7, 2026, marks a strategic transition for the Worcester-based institution as it prepares for a change in leadership this summer.
The appointment follows a unanimous vote by the board to approve the nomination put forward by UMass President Marty Meehan. Dr. McManus, who is already a well-established figure within the medical school’s ecosystem, is expected to step into the role in July, ensuring a seamless handover of administrative duties.
He will succeed Dr. Michael Collins, the outgoing chancellor who announced his intention to retire last year. The transition comes at a pivotal time for the medical school, as it continues to expand its footprint in biomedical research and clinical care within the Commonwealth of Massachusetts.
A Proven Leader Within the Institution
Choosing Dr. McManus represents a move toward continuity. As a “known quantity” at the school, McManus brings an intimate understanding of the institution’s internal culture, its faculty needs, and its relationship with the broader University of Massachusetts system. While the board’s deliberations were conducted virtually, the unanimous nature of the vote suggests a strong consensus on his ability to maintain the school’s current trajectory.
The selection process for a medical school chancellor is typically rigorous, involving an evaluation of a candidate’s ability to balance academic excellence with the financial and operational complexities of a modern research university. By appointing a leader from within, the board minimizes the “learning curve” often associated with external hires, allowing the new chancellor to focus immediately on strategic goals rather than institutional orientation.
The Transition Timeline
The handover from Dr. Collins to Dr. McManus is structured to provide stability for students, faculty, and research partners. The transition is scheduled to conclude by the start of the next academic cycle.
| Key Milestone | Date/Timeline |
|---|---|
| Board Approval of Nomination | April 7, 2026 |
| Retirement Announcement (Dr. Collins) | 2025 (Last Year) |
| Official Start Date (Dr. McManus) | July 2026 |
Impact on the UMass Chan Community
The appointment of David McManus as the next chancellor of UMass Chan Medical School is likely to be viewed as a stabilizing force for several key stakeholders. For the faculty and medical residents, the continuity of leadership reduces uncertainty regarding tenure tracks, research grants, and departmental funding.
For the city of Worcester and the surrounding region, the medical school serves as a primary economic engine and a critical provider of healthcare. The chancellor’s office manages the intersection between academic medicine and public health delivery; a leader familiar with the local landscape is well-positioned to maintain partnerships with community health centers and regional hospitals.
the appointment reflects President Marty Meehan’s vision for the university system. By aligning the medical school’s leadership with the broader UMass goals, the administration aims to strengthen the synergy between the different campuses and their respective research missions.
Strategic Priorities for the New Chancellor
While the specific agenda for Dr. McManus’s tenure has not been fully detailed, the incoming chancellor will likely inherit several critical mandates:
- Research Expansion: Continuing to attract federal funding and private partnerships for breakthrough medical research.
- Workforce Development: Addressing the shortage of primary care physicians in Massachusetts by expanding medical education and residency programs.
- Clinical Integration: Enhancing the bridge between laboratory discovery and bedside patient care.
- Institutional Sustainability: Managing the school’s budget and infrastructure in an evolving economic climate for higher education.
The Legacy of Dr. Michael Collins
The departure of Dr. Michael Collins marks the end of a significant era at UMass Chan. Under his leadership, the school has seen substantial growth in its research profile and a deepening of its commitment to health equity. His retirement, announced last year, set the stage for a deliberate search for a successor who could not only preserve these achievements but build upon them.
The seamless transition to Dr. McManus suggests that the goals established during the Collins era are expected to remain the cornerstone of the institution’s mission. The overlap in leadership—from the April appointment to the July start date—allows for a direct transfer of institutional knowledge and ongoing projects.
Note: This coverage is provided for informational purposes and does not constitute medical or professional academic advice.
The next official checkpoint for the institution will be the formal installation of Dr. McManus in July, where he is expected to outline his primary objectives for the upcoming academic year. Further updates regarding the transition will be provided via the University of Massachusetts official communications channels.
We invite readers to share their perspectives on this leadership change in the comments below or share this story with the UMass community.
